Prostate cancer treatments have changed more in the last five years than in the previous twenty. Yet some of the most important options for patients are not on pharmacy shelves yet. They are moving through the FDA pipeline right now.
As of October 2026, one major drug combination is under active FDA review with a decision expected before the end of the year. Another experimental immunotherapy just earned Fast Track status. Both could change what your oncology team offers you, and when.
If you or someone you love is living with advanced prostate cancer, this article explains which treatments are soon-to-be FDA-approved, how they work, and the steps you can take today to be ready for them.
These pipeline therapies follow a landmark summer of FDA approvals:
June 12, 2026 — Truqap (capivasertib): Approved with abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 trial.
July 31, 2026 — Pluvicto (lutetium Lu-177 vipivotide tetraxetan): Expanded to PSMA-positive metastatic hormone-sensitive prostate cancer, combined with hormone-blocking pills, based on the PSMAddition trial.
One theme connects all of these advances. Treatment is moving earlier in the disease, and it is increasingly matched to the specific biology of each person's tumor.
A note on terms: the FDA now uses the phrase "androgen pathway modulation-naïve or -sensitive" for what most patients know as hormone-sensitive or castration-sensitive prostate cancer (mHSPC or mCSPC).
The Frontrunner Under Active FDA Review: Talzenna + Xtandi
The treatment closest to approval is a two-drug combination from Pfizer: Talzenna (talazoparib) plus Xtandi (enzalutamide). In July 2026, the FDA granted Priority Review to Pfizer's supplemental application. The FDA's action date (PDUFA date) falls in the fourth quarter of 2026.
Who it is for
The application covers men with metastatic castration-sensitive prostate cancer (mCSPC) whose tumors carry a mutation in a homologous recombination repair (HRR) gene, such as BRCA1 or BRCA2.
This matters because the combination is already approved for later-stage, castration-resistant disease. This filing would move it earlier, to the point when the cancer still responds to hormone therapy.
How the two drugs work together
Think of a cancer cell as a factory that needs fuel and a repair crew to keep running.
Xtandi cuts off the fuel. It is an androgen receptor pathway inhibitor (ARPI). Prostate cancer cells use male hormones like testosterone to grow. Xtandi blocks the receptor those hormones act on, so the growth signal never lands.
Talzenna disables the repair crew. It is a PARP inhibitor. Cancer cells with HRR mutations already have a broken DNA repair system. They lean on a backup repair protein called PARP. Talzenna shuts PARP down, so damaged DNA builds up, and the cancer cell dies.
Together, they hit harder. Research suggests that blocking the androgen pathway can further weaken DNA repair, making PARP inhibition more effective.
What the evidence shows
The application rests on the Phase 3 TALAPRO-3 trial of 599 men with HRR-altered mCSPC.
Overall: The combination cut the risk of cancer progression or death by 52% compared with Xtandi alone.
BRCA1/2 mutations: The risk reduction was 63%.
Other HRR mutations: The risk reduction was 43%.
Survival: Overall survival data are still early, but the trend favored the combination.
What Priority Review means: The FDA aims to act within six months instead of the standard ten. It is reserved for drugs that may offer a significant improvement over current options. It does not guarantee approval.
Deep Dive Into the FDA Pipeline: The Fast Track Innovators
Further back in the FDA pipeline, a new kind of immunotherapy is gaining speed. In October 2026, the FDA granted Fast Track designation to VIR-5500, developed by Vir Biotechnology, which has built momentum with Astellas Pharma ahead of late-stage development.
What Fast Track status means
Fast Track is not an approval. It is a signal that the FDA sees promise in a drug for a serious condition with an unmet medical need.
More FDA contact: The developer can meet with the FDA more often to align on trial design.
Rolling review: Parts of the application can be submitted as they are ready, rather than all at once.
Faster paths later: The drug may qualify for Priority Review or Accelerated Approval if data support it.
Who VIR-5500 is for
VIR-5500 is being studied in late-line metastatic castration-resistant prostate cancer (mCRPC). These are men whose cancer has kept growing after hormone therapy, chemotherapy, and often several other treatments. Options at this stage are limited.
How a T-cell engager works
Your immune system has soldiers called T cells. Cancer is good at hiding from them. A T-cell engager (TCE) acts like a bridge between the two.
One end grabs the cancer cell. VIR-5500 locks onto PSMA, a protein found in high amounts on most prostate cancer cells.
The other end grabs a T cell. It binds a T-cell protein called CD3.
The T cell attacks. With the two pulled together, the T cell recognizes the cancer cell and destroys it.
Why "dual-masked" matters
Earlier T-cell engagers often caused serious side effects, especially cytokine release syndrome (CRS), a body-wide inflammatory reaction. VIR-5500 uses a PRO-XTEN dual-masking design.
Masked in the bloodstream: The drug circulates in an inactive, "masked" form.
Unmasked at the tumor: Enzymes found in the tumor environment remove the masks, switching the drug on mainly where the cancer is.
Possibly less frequent dosing: The masking may also help the drug last longer in the body.
Early results
The phase 1 study enrolled 58 heavily pretreated men, with a median of four prior lines of therapy. At the higher every-three-week doses:
PSA response: 82% of evaluable patients saw their PSA drop by at least half.
Tumor shrinkage: 45% of patients with measurable tumors had an objective response.
Safety: CRS was mostly grade 1, with no grade 3 CRS and no immune-related nerve toxicity (ICANS) reported.
These are small, early numbers. Phase 3 trials are expected to begin in 2027.
What This Means for Prostate Cancer Patients and Caregivers
The biggest takeaway is simple: testing now decides treatment. Every therapy in this article is matched to a specific tumor feature. Without the right test, a patient cannot qualify, no matter how well the drug might work for them.
Test | What it looks for | Therapies it can unlock |
|---|---|---|
Genetic testing (tumor and/or inherited) | HRR gene mutations, such as BRCA1/2 | Talzenna + Xtandi (approved in mCRPC; under active FDA review for mCSPC) |
PTEN immunohistochemistry (tissue stain) | Loss of the PTEN protein | Truqap + abiraterone for mHSPC (requires an FDA-authorized test) |
PSMA PET scan | PSMA protein on cancer cells | Pluvicto; PSMA-targeted trials such as VIR-5500 |
Steps you can take now
Ask about genetic testing early. Major guidelines recommend genetic testing for men with metastatic prostate cancer. Ask whether you have had both tumor (somatic) and inherited (germline) testing. They can find different mutations.
Ask about PTEN status. This is a separate tissue test. It is not part of a standard genetic panel.
Ask whether a PSMA PET scan fits your situation. It shows whether your cancer expresses PSMA, the target for Pluvicto and many pipeline drugs.
Keep your records together. Save biopsy reports, test results, and scan reports. A new treatment or trial may need them on short notice.
Tell your family about inherited results. A germline BRCA or HRR mutation can raise cancer risk for relatives, including women in the family.
Ask what is coming next. Questions like "Would I qualify for Talzenna plus Xtandi if it is approved?" or "Is there a trial that fits my profile?" help your team plan ahead.
For caregivers
You are often the one tracking appointments and paperwork. Bring a written list of these questions to the next visit. Ask the care team to write down which tests have been done and which are still pending.
Conclusion: Hope Is Already in the Pipeline
The prostate cancer treatments that are soon to be FDA-approved are not distant promises. Talzenna plus Xtandi could reach men with HRR-mutated, hormone-sensitive disease before the end of 2026. VIR-5500 shows that new immune-based approaches are gaining ground for men who have run out of standard options.
Every one of these advances started the same way: with patients who joined a clinical trial. TALAPRO-3, CAPItello-281, and PSMAddition each enrolled hundreds of men. Clinical trials are the bridge between today's standard of care and tomorrow's approvals. For some patients, a trial is the earliest way to reach a therapy that is still in the FDA pipeline.
Ask your oncology team two questions at your next visit: "Have I had every test that could open a new treatment for me?" and "Is there a clinical trial that fits my cancer?" The answers could put you at the front of what comes next.
